Dermira, Inc.
18
1
2
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
56%
10 trials in Phase 3/4
69%
11 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Role: collaborator
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Role: collaborator
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Role: collaborator
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Role: collaborator
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Role: collaborator
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Role: collaborator
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Role: collaborator
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
Role: lead
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Role: lead
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
Role: lead
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne
Role: lead
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Role: lead
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Role: lead
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
Role: lead
A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel
Role: lead
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
Role: lead
A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis
Role: lead
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
Role: collaborator
All 18 trials loaded